TEM1657 is a drug candidate that was discovered and optimized to Plant Advanced Technologies SA’s (PAT) know-how and that was patented in 2016. Results at preclinical stage in the treatment of psoriasis show similar efficacy as the market reference corticosteroids, without side effects. The input of this asset in TEMISIS – a wholly-hold subsidiary – will allow to finance further clinical development, without any risk and dilution of existing PAT shareholders while enjoying capital gains if successful. Ultimately TEMISIS will grant exploitation licences to large pharmaceutical groups, while positioning PAT as the producer of this active compound once launched on the market. This new subsidiary should reinforce PAT’s positioning on the pharmaceutical market and give rise to a significant leverage effect in the near future.